- Promino Nutritional Sciences Inc. (CSE: MUSL, OTC: MUSLF) launches its second preclinical study to combat muscle loss during chemotherapy.
- The study targets muscle preservation in breast and prostate cancer patients using a patented essential amino acid blend.
- Results will inform future human trials and potential collaborations with North American oncology institutions.
Promino Nutritional Sciences Inc. (CSE: MUSL, OTC: MUSLF) has announced the commencement of its second preclinical study. This research aims to evaluate the effectiveness of the company's patented essential amino acid (EAA) blend in reducing muscle loss during chemotherapy for breast and prostate cancer patients.
Dr. Patrick Gunning, a prominent figure in medicinal chemistry and molecular therapeutics and Chief Scientific Advisor to Promino, leads the study. The trials will use murine models to explore the EAA blend's potential in preventing cachexia, a severe muscle wasting condition that often accompanies chemotherapy.
The study addresses the large populations affected by these types of cancers—breast cancer, impacting over 2.3 million women annually, and prostate cancer, affecting 1.4 million men each year. Promino's EAA formulation, developed by Dr. Robert Wolfe of the University of Arkansas, is designed to stimulate muscle protein synthesis even under metabolic stresses, which are common during chemotherapy.
Through this initiative, Promino aims to provide insights that will advance future human trials and foster potential clinical collaborations with leading oncology institutions across North America. The ultimate goal is to support the development of nutritional tools to combat treatment-related muscle wasting, thereby improving treatment tolerance, recovery outcomes, and quality of life for cancer patients.
For more information on Promino's innovative research and its commitment to advancing clinical nutrition, visit their website at www.drinkpromino.com.
